SEMA6D Expression and Patient Survival in Breast Invasive Carcinoma

Abstract EN

Breast cancer (BC) is the second most common cancer diagnosed in American women and is also the second leading cause of cancer death in women.

Research has focused heavily on BC metastasis.

Multiple signaling pathways have been implicated in regulating BC metastasis.

Our knowledge of regulation of BC metastasis is, however, far from complete.

Identification of new factors during metastasis is an essential step towards future therapy.

Our labs have focused on Semaphorin 6D (SEMA6D), which was implicated in immune responses, heart development, and neurogenesis.

It will be interesting to know SEMA6D-related genomic expression profile and its implications in clinical outcome.

In this study, we examined the public datasets of breast invasive carcinoma from The Cancer Genome Atlas (TCGA).

We analyzed the expression of SEMA6D along with its related genes, their functions, pathways, and potential as copredictors for BC patients’ survival.

We found 6-gene expression profile that can be used as such predictors.

Our study provides evidences for the first time that breast invasive carcinoma may contain a subtype based on SEMA6D expression.

The expression of SEMA6D gene may play an important role in promoting patient survival, especially among triple negative breast cancer patients.